CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine

    NEXT STORY
    Curetis to Present at Solebury Trout European Biotech Investor Day in NYC
    PREV STORY
    Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global Pericarditis Drugs Market Research Report 2019-2023 – Key Players are AstraZeneca, Bayer, Johnson & Johnson Services, Pfizer, and Takeda Pharmaceutical Co

    author_avatar
    NASDAQ Market News

    Flexion Therapeutics Reports Third Quarter 2016 Financial Results

    Successfully completed the transfer of the Zilretta™ manufacturing technology to Patheon - on track ...

    author_avatar
    NASDAQ Market News

    Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference

    ALPHARETTA, Ga., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News